What question did this study set out to answer?

Evaluate the role of CYP2C19 genotyping in managing acute coronary syndrome for patients at high bleeding risk.

May 8, 2026Open Access

2025 Acute Coronary Syndrome Guideline: Missing the Boat on CYP2C19 Genotyping

Resultado clave

CYP2C19 genotyping is inadequately recommended in the 2025 Acute Coronary Syndrome guidelines, representing a missed opportunity especially for patients at high bleeding risk.

Puntos clave

Evaluate the role of CYP2C19 genotyping in managing acute coronary syndrome for patients at high bleeding risk.
Review of existing guidelines regarding acute coronary syndrome management.
Analysis of recommendations for CYP2C19 genotyping in high-risk populations.
Identified lack of emphasis on CYP2C19 genotyping in current guidelines for acute coronary syndrome.
Highlighted potential implications for patient safety and treatment efficacy.

Resultado numérico

Tasa de eventos absoluta: 0% vs 0%

Resumen

genotyping, especially for those at high bleeding risk.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Me gusta

Guardar

Ver artículo completo

Cite This Study

Cavallari et al. (Wed,) reported a other. CYP2C19 genotyping is inadequately recommended in the 2025 Acute Coronary Syndrome guidelines, representing a missed opportunity especially for patients at high bleeding risk.

synapsesocial.com/papers/69fd7e00bfa21ec5bbf06272 https://doi.org/https://doi.org/10.1161/jaha.125.047768